Capricor Therapeutics, Inc.
CAPR
Rank in Stocks
#11383
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which... Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (βDMDβ), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Share Price
$9.85
Last synced: 2026-11-09
Market Cap
$570.43M
Change (1 day)
9.44%
Change (1 year)
58.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Capricor Therapeutics, Inc. (CAPR)
Category
Healthcare
Operating Margin for Capricor Therapeutics, Inc. (CAPR)
Operating Margin as of November 2026 TTM: 0.00%
According to Capricor Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Capricor Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -191.13% | 99.86% |
| 2023 | -95.63% | -91.78% |
| 2022 | -1,163.93% | -86.39% |
| 2021 | -8,549.86% | 93.76% |
| 2020 | -4,412.56% | 473.42% |
| 2019 | -769.52% | -16.10% |
| 2018 | -917.24% | 90.12% |
| 2017 | -482.45% | -9.35% |
| 2016 | -532.19% | 59.34% |
| 2015 | -334.00% | 131.27% |
| 2014 | -144.42% | -89.47% |
| 2013 | -1,371.73% | 9.91% |
| 2012 | -1,248.08% | 245.20% |
| 2011 | -361.55% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | -9,368.84% | 1,328.11% |
| 2006 | -656.03% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | -100.00% |
| 2003 | -739.79% | 377.84% |
| 2002 | -154.82% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Capricor Therapeutics, Inc.'s operating margin
What was Capricor Therapeutics, Inc.'s operating margin in 2025?
In 2025, Capricor Therapeutics, Inc.'s operating margin was 0.00%, compared with -191.13% in 2024.
How has Capricor Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Capricor Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-8,549.86%).
How does Capricor Therapeutics, Inc.'s operating margin compare with similar companies?
Capricor Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.